Pharmaceutical Statistics

Table of Contents

Volume 19 Issue 3 (May 2020)


Issue Information

Issue Information

  • Author:
  • Pub Online: May 04, 2020
  • DOI: 10.1002/pst.1959 (p 165-167)


The win ratio: Impact of censoring and follow‐up time and use with nonproportional hazards

  • Author: Gaohong Dong, Bo Huang, Yu‐Wei Chang, Yodit Seifu, James Song, David C. Hoaglin
  • Pub Online: Oct 31, 2019
  • DOI: 10.1002/pst.1977 (p 168-177)

Empowering phase II clinical trials to reduce phase III failures

  • Author: Daniele De Martini
  • Pub Online: Nov 14, 2019
  • DOI: 10.1002/pst.1980 (p 178-186)

Nonlinear mixed‐effects models with misspecified random‐effects distribution

  • Author: Reza Drikvandi
  • Pub Online: Oct 29, 2019
  • DOI: 10.1002/pst.1981 (p 187-201)

Cancer immunotherapy trial design with delayed treatment effect

  • Author: Jianrong Wu, Jing Wei
  • Pub Online: Nov 15, 2019
  • DOI: 10.1002/pst.1982 (p 202-213)

Two‐stage phase II survival trial design

  • Author: Jianrong Wu, Li Chen, Jing Wei, Heidi Weiss, Aman Chauhan
  • Pub Online: Nov 21, 2019
  • DOI: 10.1002/pst.1983 (p 214-229)

Comparisons of outlier tests for potency bioassays

  • Author: Perceval Sondag, Lingmin Zeng, Binbing Yu, Harry Yang, Steven Novick
  • Pub Online: Nov 24, 2019
  • DOI: 10.1002/pst.1984 (p 230-242)

Sequential parallel comparison design with two coprimary endpoints

  • Author: Gosuke Homma, Takashi Daimon
  • Pub Online: Dec 12, 2019
  • DOI: 10.1002/pst.1987 (p 243-254)

Covariate adjustment for randomized controlled trials revisited

  • Author: Jixian Wang
  • Pub Online: Dec 21, 2019
  • DOI: 10.1002/pst.1988 (p 255-261)

Multistate modeling of clinical hold in randomized clinical trials

  • Author: Alexandra Nießl, Jan Beyersmann, Anja Loos
  • Pub Online: Dec 10, 2019
  • DOI: 10.1002/pst.1989 (p 262-275)

Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs

  • Author: Claire L. Smith, Zachary Thomas, Nathan Enas, Katharine Thorn, Michael Lahn, Karim Benhadji, Ann Cleverly
  • Pub Online: Jan 05, 2020
  • DOI: 10.1002/pst.1990 (p 276-290)

A Bayesian approach to sequential analysis in post‐licensure vaccine safety surveillance

  • Author: Rongxia Li, Brock Stewart, Charles Rose
  • Pub Online: Dec 22, 2019
  • DOI: 10.1002/pst.1991 (p 291-302)

Enrichment designs using placebo nonresponders

  • Author: Norbert Benda, Britta Haenisch
  • Pub Online: Jan 03, 2020
  • DOI: 10.1002/pst.1992 (p 303-314)

A flexible multi‐domain test with adaptive weights and its application to clinical trials

  • Author: Yang Zhao, Qifeng Yu, Stephen L. Lake
  • Pub Online: Dec 30, 2019
  • DOI: 10.1002/pst.1993 (p 315-325)

Discussion on statistical analysis of carcinogenicity studies with an early terminated treated group

  • Author: Jim Saul, Kelly Ashcroft‐Hawley
  • Pub Online: Dec 12, 2019
  • DOI: 10.1002/pst.1994 (p 326-334)
Page:   1 2 Next

Related Topics

Related Publications

Related Content

Site Footer


This website is provided by John Wiley & Sons Limited, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ (Company No: 00641132, VAT No: 376766987)

Published features on are checked for statistical accuracy by a panel from the European Network for Business and Industrial Statistics (ENBIS)   to whom Wiley and express their gratitude. This panel are: Ron Kenett, David Steinberg, Shirley Coleman, Irena Ograjenšek, Fabrizio Ruggeri, Rainer Göb, Philippe Castagliola, Xavier Tort-Martorell, Bart De Ketelaere, Antonio Pievatolo, Martina Vandebroek, Lance Mitchell, Gilbert Saporta, Helmut Waldl and Stelios Psarakis.